

Leading intimate healthcare Roadshow presentation 9M 2016/17

Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care


Forward-looking statements

The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the information available to Coloplast at this time.

Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company's financial outcomes.



Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 33% before one-off adjustment for Veterans Affairs



* Coloplast has identified the incorrect management of the 2009 agreement and is in dialogue with the U.S. Veterans Affairs to settle the matter. The matter relates to Continence Care products and is treated as a one-off adjustment recognized directly in the Q3 revenue. The matter has not affected the organic growth rate for the reporting period.


Page 3


Q3 Highlights

- Q3 organic growth of 8% (6% reported growth)
 - Reported revenue in Q3 negatively affected by DKK 90m estimated one-off adjustment related to incorrect management of contract with U.S. Department of Veterans Affairs*
- US Chronic Care business reported double-digit organic sales growth in Q3
- Growth in WC negatively impacted by price reforms in Greece and France, offset by improved momentum in China
- Q3 EBIT margin of 33% in constant exchange rates, before one-off adjustment for Veterans Affairs, on par with last year
- Updated financial guidance for 2016/17:
 - Organic revenue growth of 7-8% and ~6% reported growth from previously 7-8%
 - EBIT margin of 33-34% in constant currencies and ~32% in reported EBIT from previously ~33%



9M organic growth of 7% with good performance across most business areas and geographies






* Estimated one-off revenue adjustment related to incorrect management of a contract with U.S. Veterans Affairs




Ostomy Care grew 7% organically in Q3 and continues to be driven by SenSura[®] range and Brava[®] accessories



- 9M organic growth of 7% (6% reported growth). Q3 organic growth of 7% (8% reported growth)
 - The acquisition of Comfort Medical contributed 1% growth to revenue in Ostomy Care in 9M and Q3
- Satisfactory growth in Q3 driven by UK, China and Russia, but negatively impacted by weaker momentum in the Netherlands
- Satisfactory growth in SenSura® portfolio in Q3 especially in UK and Germany, mainly driven by SenSura®Mio Convex
 - SenSura[®]Mio Convex relaunch proceeding successfully
- Growth in Brava[®] accessories in Q3 driven by especially China, UK and France
 - **Brava® Protective Seal** continues to take market share in the ring segment, the largest accessories market segment




Continence Care grew 10% in Q3 driven by SpeediCath[®] intermittent catheters and strong performance in the US



- 9M organic sales growth of 8% (7% reported growth). Q3 organic growth of 10% (12% reported growth)
 - The acquisition of Comfort Medical contributed 2% growth to revenue in Continence Care in 9M and 3% growth in Q3
- Q3 growth driven by SpeediCath[®] Compact catheters in particular in UK, US and France
- Growth in SpeediCath[®] Flex in Q3 driven by Europe and US
- Growth in standard catheters in Q3 was driven by US, Saudi Arabia and Argentina
- Sales in urine bags and urisheaths in Q3 was driven by France, but counterbalanced by challenges in UK and the Netherlands
- **Peristeen**[®] sales remains satisfactory in most markets, especially in Southern Europe and US




Urology Care grew 10% in Q3 driven by US sales of Altis[®] slings and Titan[®] penile implants



- 9M organic growth of 11% (12% reported growth). Q3 organic growth of 10%
- Growth in Q3 driven by the US and Europe
- Strong growth in sales of Altis[®] slings and Titan[®] penile implants in the US market
- Sales of disposable surgical products was positively impacted by sales in Saudi Arabia and Europe




WC negatively impacted by price reforms in Greece and France and weak momentum in Emerging Markets



- 9M organic sales growth of 0% for WSC (1% reported growth). Q3 organic growth for WSC of 1%
- 9M organic growth of 3% for Wound Care in isolation, and negative 1% in Q3. Wound Care negatively impacted in Q3 by:
 - Price reform in France
 - De-stocking in Greece following price reform
- Sales of Biatain[®] foam dressings positively impacted by improved momentum in China WC in Q3
- Positive growth in Skin Care in Q3 due to low sales in Q3 last year
- Growth in Q3 driven by Skin Care in US and Wound Care in China, both posting double-digit growth rates



9M EBIT in constant currencies & before one-off adjustment for VA grew 9% corresponding to an EBIT margin of 33%




* Estimated DKK 90m one-off revenue adjustment related to incorrect management of a contract with U.S. Veterans Affairs

- EBIT grew 4% to DKK 3,705m with a reported margin of 32% (33% in constant currencies, before one-off revenue adjustment) compared to 33% last year
- Gross margin of 68% in line with last year
 - Continued efficiency gains and positive impact from relocation manufacturing of SenSura[®] Mio and Compeed to Hungary
 - Negatively impacted by wage inflation in Hungary, product mix, depreciation and restructuring costs of DKK 16m
 - Reduction of production employees in Denmark from 700 to 400 in 2017/18 on track
- Distribution-to-sales of 28% (28% in 9M 2015/16)
 - Investments in sales and marketing initiatives, primarily in the US and Wound Care
- Admin-to-sales of 4% on par with last year
- R&D costs increased 15% compared to last year due to increased activity. R&D-to-sales at 4% compared to 3% last year



FCF adjusted for Mesh settlements, acquisition of Comfort Medical and tax payments was in line with last year



Comments

- Free cash flow was positive DKK 322m compared to positive DKK 1,643m in 9M 2015/16
 - EBITDA DKK 201m higher than same period last year
 - NWC-to-sales of 26%, 2%-points higher than FY 2015/16 primarily due to higher inventory in connection with closure of backorders and product launches
 - Negative impact from deposits into escrow account and other costs in relation to US Mesh litigation (total YTD payments of DKK 1.7bn)
 - Negative impact from timing of tax payments last year
 - Acquisition of Comfort Medical for DKK 1.1bn
 - CAPEX-to-sales of 4% in line with last year
 - Net sale of bonds decreased by DKK 142m
- FCF ex. Mesh impact and Comfort Medical of DKK 2,527m compared to DKK 2,905m last year. Difference explained by timing of tax payments and hence underlying FCF was in line with last year

*FCF adjusted for Mesh payments in 2013/14, 2014/15, 2015/16. Adjustment for Mesh payments includes DKK 500m insurance coverage in 2013/14 and 2014/15 combined. 9M 2016/17 FCF adjusted for Mesh payments and acquisition of Comfort Medical.



Updated financial guidance for 2016/17

	Guidance 16/17	Guidance 16/17 (DKK)	Long term ambition
Sales growth	7-8% (organic)	~6% from 7-8%	7-9% p.a.
EBIT margin	33-34% (constant exchange rates)	~32% from ~33%	+50-100 bps p.a.
CAPEX (DKKm)		~700	4-5% of sales
Tax rate		~23%	







Leading intimate healthcare Introduction to Coloplast



Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care

Coloplast has four business areas all with global sales presence








Coloplast specializes in intimate healthcare needs

	Who are our typical users	How do we help them?		
Ostomy Care	People who have had their intestine redirected to an opening in the abdominal wall	SenSura[®] Mio Ostomy bag		
Continence Care	People in need of bladder or bowel management	SpeediCath [®] Flexible male urinary catheter		
Urology Care	People with dysfunctional urinary and reproductive systems	Titan[®] OTR Penile implant	- Company	
Wound Care	People with difficult-to-heal wounds	Biatain[®] Silicone Foam wound dressing	Attention in	



Intimate healthcare is characterized by stable industry trends





Coloplast has strong market positions in Europe and great commercial potential outside Europe

 Europe Developed Emerging Ostomy 		Continence	Urology	Wound Care	
Addressable market Size in DKK Growth in %	15-16bn 4-5%	~12bn 5-6%	~10bn 3-5%	17-19bn 3-5%	
Coloplast regional market shares	40 - 50% 15 - 25% 35 - 45%	45 - 55% 20 - 30% 20 - 30%	10 - 20% 5 - 15% 5 - 15%	5 - 15% 0 - 10% 10 - 20%	
Coloplast total market share	35-40%	~40%	10-15%	7-9%	
Key competitors	ConvaTec III	Wellspect BANRID * Hollister	ETHICON Marcing science for life*	Sevential Sevent	
Key drivers and limiters	 Ageing population Increasing access to healthcare Health care reforms Re-use of products outside Europe 	 Ageing population IC penetration potential Up-selling Health care reforms Commoditization 	 Ageing, obesity Underpenetration Cost consciousness Clinical requirements Less invasive/office procedures 	 Ageing, obesity, diabetes New technologies Healthcare reforms Competition Community treatment 	
Coloplast A/S - Ostomy Care / Contir	nence Care / Wound & Skin Care / Urology Care	Page 16	* Bard has been acquired by Becton Dicki	nson and Co.	

Coloplast's new strategy will drive revenue and earnings growth across 4 major themes



Unique user focused market approach

Unparalleled efficiency

2

3

4

Strong leadership development





LEAD20 – an update on our direction towards 2020

Superior products and innovation



SenSura[®] Mio Hospital Assortment Launched in 2017



SenSura[®] Mio Convex Launched in 2015 Relaunched in 2017



SpeediCath[®] Flex Launched in 2016



Brava[®] Protective Seal Launched in 2016



Biatain[®] Silicone Sizes & shapes Launched in 2016

Comfeel® Plus Relaunched in 2016

4% R&D to sales YTD 16/17

Unique user-focused market approach



+ 500,000 enrolments



Live in +20 markets

+ 1 million users in our Coloplast database



Unparalleled efficiency Innovation Excellence Production ramp-up directly from Hungary/China:







SpeediCath[®]

Flex

SenSura® Mio SenSura® Mio Hospital Convex assortment

Reduction of production employees in Denmark



- 100 FTEs in DK 2015/16
- 100 FTEs as of Q3 2016/17
- In total, 300 FTEs by
- 2017/18
- On track to deliver DKK 80-100m saving by 2017/18





We have launched innovative products across business areas and invested heavily in Consumer activities

Continence Care

Ostomy Care

Consumer Care



Wound Care





Urology Care





Consumer










We have now initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face



2) Source: Ostomy Life Study 2016, ECET Coloplast Pre-Event (n=4,235)3) Source: OC Usage Pattern Study 2014.



1) Source: Coloplast IC user survey, January 2016 (n=2,942)

We will continue to push for efficiency gains across Global Operations and Business Support




Business support

- Efficiency improvement in the subsidiaries, HQ and business support centre
- Subsidiaries to focus on commercial priorities
- Add new tasks performed by our Business Centre on an ongoing basis






Expansion relies on our organisation and strong leadership development is key to support growth






The strategy will commit up to DKK 2bn in new investments towards 2020







Profitability uplift to be driven by scalability and efficiency improvements






We will continue to deliver strong and attractive free cash flows ...








• Widen factory footprint – factory extensions and/or greenfield investments

Coloplast

1) Impacted by provision for Mesh litigation

2) Gross investments in PPE

... and attractive cash returns despite large investments in commercial and expansion activities



Comments

- Coloplast returns excess liquidity to shareholders in the form of dividends and share buy-backs
- Dividend is paid twice a year after the half-year and full-year financial reporting
 - H1 2016/17 interim dividend of DKK 4.50 per share for a total interim dividend of DKK 955m
- DKK 1bn share buy-back to be completed before end of 2016/17 has been completed
 - First part of DKK 500m completed in 2015/16
 - Second part of DKK 500m initiated in Q2 2016/17 and completed in Q4 2017



* Dividends paid out in the year are the actual cash payments of which the majority relates to dividend proposed in the previous financial year ** Pay-out ratio calculated as dividend proposed in the financial year/Net profit for the financial year. Pay-out ratio for 2013/14, 2014/15 and 2015/16 is before special items related to Mesh litigation

Our long-term guidance will continue to deliver strong value creation




EBIT margin annual improvement

50-100 bps



In sum, we believe Coloplast can continue to deliver stable shareholder returns through ...



Comments

- Stable market trends in our Chronic Care business
- Strong retention program and innovative DtC activities
- Increased focus on growing the business outside Europe
- Additional improvements in manufacturing by leveraging on global operations footprint
- European leverage will provide funds for further investments in sales initiatives
- Resulting in strong free cash flow generation and high return on invested capital

*FCF adjusted for Mesh payments in 2013/14, 2014/15, 2015/16. Adjustment for Mesh payments includes DKK 500m insurance coverage in 2013/14 and 2014/15 combined.

YTD 2016/17 FCF adjusted for Mesh payments and acquisition of Comfort Medical.

** Before special items. Special items Q2 2013/14 includes DKK 1bn net provision. Special items Q4 2014/15 includes DKK 3bn provision. Special items Q4 2015/16 includes DKK 0.75bn provision.



Leading intimate healthcare Appendices

Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care




The Coloplast share (COLO'B-KO)

Coloplast share listed on Nasdaq Copenhagen since 1983

~**116 billion DKK** (~18.5 billion USD) **market cap** @ ~540 DKK per share (incl. A shares)

Two share classes:

- 18m A shares carry 10 votes (family)
- 198m B shares carry 1 vote (freely traded)
- Free float approx. 55% (B shares)




Note: Share capital ownership as per June 2017



Capital structure

Comments

- Overall policy is that excess liquidity is returned to shareholders through a combination of dividends and share buybacks
- Interest bearing debt will be raised in connection with a major acquisition or to support dividends
- Share buy-backs of DKK 500m per year expected
- Bi-annual dividends
- Coloplast has entered into loan facilities to fund Mesh litigation settlements and the acquisition of Comfort Medical
- Interest-bearing net debt of DKK 1,920m at 30 June 2017






* Before special items. Special items Q2 2013/14 includes DKK 1bn net provision. Special items Q4 2014/15 includes DKK 3bn provision. Special items Q4 2015/16 includes 0.75bn provision.




Key Value Ratios



* Before special items. Special items Q2 2013/14 includes DKK 1bn net provision. Special items Q4 2014/15 includes DKK 3bn provision. Special items Q4 2015/16 includes 0.75bn provision

** Gross CAPEX including investment in intangible assets

Coloplast revenue development by business area




Continence Care

Ostomy Care




Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care

Urology Care



Wound & Skin Care




Coloplast revenue development by geography and total




Emerging Markets


Europe




Other Developed Markets




Coloplast group



Segment operating profit







Note: Excludes shared/non-allocated costs

*Includes DKK 90m one-off revenue adjustment related to incorrect management of a contract with U.S. Veterans Affairs

Segment Operating Profit DKKm* Segment Operating Profit Margin (%)*



Exchange rate exposure and hedging policy

					initial exchai
DKK	GBP	USD	HUF	EUR	
Average exchange rate 2015/16 ¹⁾	956	671	2.39	745	
Spot rate, 19 Jan 2017	858	699	2.41	744	
Spot rate, 1 May 2017	877	682	2.38	744	-130
Spot rate, 14 August 2017	819	630	2.45	744	
Estimated average exchange rate 2016/17 ²⁾	851	673	2.41	744	-290
Change in spot rate compared with the average exchange rate 2015/16	-11%	0%	1%	0%	USD
Change in spot rate at 14 August 2017 compared with the average exchange rate 2016/17	-4%	-6%	2%	0%	Revenue (DKI

12 months exposure from 10% initial exchange rate drop



Hedging Policy

To achieve the objective of a stabile Profit before Tax we hedge:

- Balance sheet items in foreign currency
- Cash flow in foreign currency up to 12 months expected CF (on average 10-12 months)

Key currencies hedged - USD, GBP, HUF


Cash flow is hedged using options and forward contracts.

1) Average exchange rate from 1 October 2015 to 30 September 2016

Financial guidance for 2016/17

2) Estimated average exchange rate is calculated as the average exchange rate year to date combined with the spot rates at 14 August 2017


Mesh litigation timeline



US Mesh litigation – Overview of current financial impact

P&L			
	2013/14 2	2014/15 2	015/16
EBIT (before special items)	4,147	4,535	4,846
Special items	-1,000	-3,000	- 750
EBIT	3,147	1,535	4,096
EBIT % (before special items) EBIT %	33 25	33 11	33 28
EDII 70	25		28

- A total of DKK 5,250m (DKK 4,750 net of insurance coverage) has been provisioned and is considered sufficient
- Currently more than 95% of known cases against Coloplast have been settled





Cash flow Actual/Expected cash flow, DKKbn

• Settlements expected to be finalised within the next 1-2 years

15/16

16/17E

17/18E

- Insurance coverage of 500 MDKK received in 2013/14 and 2014/15
- 1,500 MDKK loan facility (2 yrs)

14/15

13/14




Timeline of SpeediCath[®] patent litigations



Health reform landscape


Europe

- France: Reimbursement pressure on WC. Reimbursement review of OC and CC
- Germany: Reimbursement pressure on OC and CC
- Netherlands: Reimbursement pressure on OC and CC
- UK: Efficiency savings under NHS reform
- Italy: Regional tenders and pricing challenges
- Greece: Reimbursement pressure on all BAs



Rest of World

- U.S.: Healthcare reform implementation ongoing
- Brazil: Macroeconomic and political challenges
- **Russia**: Macroeconomic and political challenges
- Saudi Arabia: Macroeconomic and political challenges







CARE helps us increase retention and improve product compliance for in excess of 500,000 enrolled consumers




CARE is a personal and "hightouch" program

Advisors available on phone

Website with reliable advice and useful self assessment tools 24/7


News, tips and inspiration directly in email or mailbox

> Free product and accessories samples






With our DtC marketing program we reach into the community







The generic model for distribution and reimbursement of our products






Comfort Medical – a direct-to-consumer business model



- On December 20, 2016, Coloplast acquired Comfort Medical for a cash consideration of USD 160m equal to approx. DKK 1.1bn on a cash and debt-free basis
- Comfort Medical is a US nation wide catheter and ostomy Direct to Consumer Durable Medical Equipment (DME) dealer
- The Company was established in 2010 in Florida
- A DME dealer provides patients with medical products and obtains reimbursement on behalf of the patient through payer contracts. Products are distributed through a third party distributor
- In the full year 2016, Comfort Medical recorded sales of approx. USD 38m or approx. DKK 270m

Business model

Comfort Medical has an inflow of patients from 3 different sources:





The rationale behind the acquisition of Comfort Medical is in line with and contributing to our US ambition

Rationale behind acquisition

- 1 An opportunity to secure patient access to superior Coloplast products
- 2 Large attractive value pool to tap into
- 3 Business model with proven commercial concept and scalable platform to drive further growth
- 4 An opportunity to accelerate hydrophilic upgrade
- 5 An opportunity to create significant value going forward







In Wound Care we are progressing with our new ambition





Introducing Ostomy Care

Disease areas

- Colorectal cancer (est. 45%)
- Bladder cancer (est. 10%)
- Diverticulitis (est. 15%)
- Inflammatory bowel disease (est. 10%)
- Other (est. 20%)

Customer groups

- Nurses, mainly stoma care nurses
- People with a stoma
- Wholesalers/distribution
- Hospital purchasers and GPOs
- Surgeons

Call points

- Hospital & community
 nurses
- Hospital buyers
- Distributors
- Dealers
- Wholesalers
- Homecare companies





SenSura® Mio Hosp. assortment SenSura® M Launched in 2017 Launched in



SenSura® Launched in 2006-2008








SenSura[®] Mio Launched in 2014



Alterna® original Launched in 1991

Distribution of revenues*

Urostomy
lleostomy
Colostomy







Introducing Ostomy Care Accessories

Market fundamentals

- Market size of DKK ~2bn
- Market growth of 6-8%
- Market share 25-30%
- Main competitors include: Hollister Adapt, ConvaTec, 3M Cavilon, Eakin

Customer groups & call points

- Nurses, mainly stoma care nurses
- People with a stoma
- Wholesalers/distributors
- Hospital purchasers and GPOs
- Surgeons

Market value by geography





Key products



Brava[®] Protective Seal Designed for leakage and skin protection



Brava[®] Elastic Tape

• Elastic so it follows the body and movements



• Reducing skin problem

Brava[®] is a range of ostomy accessories designed to

users feel secure. Brava[®] was launched in April 2012

reduce leakage or care for skin, to make our end-

and the range includes 12 different products.

• Reducing skin problems without affecting adhesion

Brava® Lubricating Deodorant

• Neutralizing odour



Brava[®] Adhesive Remover • Sting free and skin friendly



Introducing Continence Care

Disease areas

- Spinal Cord Injured, SCI •
- Spina Bifida, SB •
- Multiple Sclerosis, MS
- Benign prostatic hyperplasia, • BPH & prostatectomy patients
- Elderly

Customer groups

- Continence or home care nurses •
- Wholesalers/distributors •
- Hospital purchasers and GPOs



Key products

SpeediCath[®] Flex Intermittent catheter Launched in 2016



SpeediCath[®] Compact Male intermittent catheter Launched in 2011



SpeediCath[®] Compact Eve

Intermittent catheter


Launched in 2014


Conveen[®] Optima External catheter Launched in 05/06



Conveen[®] Security+ Launched in 2013

Distribution of revenues







Main call points

- Rehabilitation centers •
- Urology wards
- Distributors, dealers & wholesalers •

Introducing Bowel Management

Disease areas

Faecal incontinence (management products only)

Customer groups

- Spinal Cord Injured, SCI
- Spina Bifida, SB
- Multiple Sclerosis, MS

Call points

- Rehab centers
- Pediatric clinics
- Urology wards

Distribution of revenues

Peristeen[®] Anal Irrigation
Anal plug

Market dynamics

- + Growing awareness
- + Huge underpenetrated and unserved population
- + New devices addressing the many unmet needs
- Still taboo area and non-focus for professionals (doctors)
- ÷ Very little patient awareness
- + Training required (nurses, patients)

Page 50

÷ Lack of reimbursement



Peristeen® Anal Irrigation Launched in 2003 Updated in 2011



Anal plug Launched in 1995



Introducing Urology Care Treatment (surgical) of urological disorders

Disease areas

- Urinary incontinence
- Pelvic organ prolapse
- Erectile dysfunction
- Enlarged prostate
- Kidney and urinary stones

Customer groups

- Surgeons
- Purchasing departments and organizations
- End customers

Call points

- Urologists
- Uro-gynaecologists
- Gynaecologists
- Purchasing departments and organizations

Key products



Titan® OTR penile implant Launched in 2008 Men's health – Surgical Urology



Isiris[®] cystoscope Launched in 2015 Single use devices




Altis® single incision sling Launched in 2012 Women's health – Surgical Urology



JJ stents Launched in 1998 Single use devices

Distribution of revenues







Introducing Wound Care

Disease areas

Chronic wounds

- Leg ulcers
- Diabetic foot ulcers
- Pressure ulcers

Customer groups & call points


Hospitals

- Wound care
 committees
- Specialist nurses/doctors
- (Purchasers)

Community

- Specialist nurses/doctors
- General practitioners
- District/general nurses
- Large nursing homes

Key products




Biatain® Silicone Foam dressing with silicone adhesive Launched in 2013



Biatain® High exudate mgt. foam dressing Launched in 1998




Biatain® Ag Antimicrobial foam dressing Launched in 2002



Comfeel® Plus Hydrocolloid dressing Relaunched in 2016

Distribution of revenues (WSC)







Introducing Skin Care

Disease areas

- Moisture associated skin damage
- Incontinence
- Skin folds & obesity
- Prevention of skin impairments

Customer groups & call points

Hospitals

- Clinical Specialists
- Supply Chain
- Value Analysis Committee

Community

- Wound Clinics
- Long Term Care
- Home Health Agencies
- Distribution

Key p	products
-------	----------



Sween[®] Broad line of skin care products Designed to increase consistency of care



Critic-Aid® Clear / AF Skin Protectant Suitable for neonate to geriatric patients




EasiCleanse Bath® Disposable Bathing Wipes Improves Patient Experience



InterDry[®] Ag Textile with antimicrobial silver complex Unique solution for skin on skin issues

Product mix







Product market for US Skin Care



Market drivers/limiters

- + Aging and obese population
- + CMS Value Based Purchasing
- + Increased focus on prevention
- + Increased importance of utilization management
- ÷ Consolidation of Providers
- ÷ Increased competition from both Channel and Manufacturers

Market trends

- Increasing size and vertical integration of health systems
- Increasing importance of prevention
- Increasing importance of utilization
 management
- Increasing scale and vertical integration of market leaders

US Skin Care at a glance

- US market size estimated at DKK
 5-6bn with 4-5% growth
- Market share: 7-9%
- Main competitors include:
 - Medline Industries
 - Sage Products
 - ConvaTec



The Coloplast organisation

Coloplast Group			
Chronic Care		Strategic Business Units	
Ostomy Care Conti	nence Care	Wound & Skin Care	Urology Care
Marketing		Marketing Sales R&D	Marketing Sales R&D
Sales Regions			
Global Operations (incl. Global R&D)			
Global Business Support Functions			



Coloplast Executive Management



Lars Rasmussen President, CEO • Born 1959 • With Coloplast since 1988



Anders Lonning-Skovgaard EVP, CFO • Born 1972 • With Coloplast since 2006



Allan Rasmussen EVP, Global Operations • Born 1967 • With Coloplast since 1992



Kristian Villumsen EVP Chronic Care • Born 1970 • With Coloplast since 2008



Corporate responsibility – Member of UN Global Compact since 2002 and recognized externally



Dow Jones Sustainability Indices

In Collaboration with RobecoSAM 🐽





THE INCLUSION OF COLOPLAST A/S IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF COLOPLAST A/S BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.



Income statement

DKKm	9M 2015/16	9M 2016/17	Change
Revenue	10,942	11,548	6%
Gross profit	7,471	7,854	5%
SG&A costs R&D costs Other operating income/expenses	-3,537 -380 8	-3,728 -436 15	5% 15% nm
Operating profit (EBIT) Net financial items Tax	3,562 -31 -812	3,705 -85 -833	4% nm 3%
Net profit	2,719	2,787	3%
Key ratios			
Gross margin EBIT margin	68% 33%	68% 32%	
Earnings per share (EPS), diluted	12.78	13.13	3%



Balance sheet

DKKm	30 June 2016	30 June 2017	Change
Balance, total	11,280	12,247	9%
Assets			
Non-current assets	4,634	5,729	24%
Current assets	6,646	6,518	-2%
of which: Inventories Trade receivables Restricted cash	1,502 2,769 1,152	1,742 2,845 769	16% 3% -33%
Marketable securities, cash, and cash equivalents	624	627	0%
Equity and liabilities			
Total equity Non-current liabilities Current liabilities of which: Trade payables	4,499 464 6,317 525	4,958 453 6,836 527	10% -2% 8% 0%
Key ratios			
Equity ratio	40%	40%	
Invested capital	6,094	8,174	34%
Return on average invested capital before tax (ROIC) $^{1)}$ Return on average invested capital after tax (ROIC) $^{1)}$	60% 46%	59% 45%	
Net asset value per share, DKK	21	23	10%

1) This item is before Special items. After Special items, ROIC before tax is 72% (2015/16: 88%), and ROIC after tax is 55% (2015/16: 68%).




Cash flow

DKKm	9M 2015/16	9M 2016/17	Change
EBITDA	3,955	4,156	5%
Change in working capital	291	-1,512	nm
Net interest payments	-84	17	nm
Paid tax	-321	-326	2%
Other	-2,139	-667	-69%
Cash flow from operations	1,702	1,668	-2%
CAPEX ¹⁾	-386	-423	10%
PPE divested	9	45	nm
Acquisition	0	-1,144	nm
Securities	318	176	-45%
Cash flow from investments	-59	-1,346	nm
Free cash flow	1,643	322	-80%
Dividends	-2,650	-2,864	8%
Net investment in treasury shares and exercise of share options	-253	-7	-97%
Net cash flow for the year	-1,260	-2,549	nm



Manufacturing setup



* Produced quantity of finished goods

** FY 2015/16 Cost of goods sold, DKK 4,649m



Production sites

Denmark

Mørdrup



Thisted



- Adhesives production
- Wound care products
- Ostomy care products
- Continence care products
- Pilot development work Adhesives, Continence care and Wound care

• Number of employees in production: ~350

Machine development & commissioning

- Ostomy care products
- Pilot development work Ostomy care
- Number of employees in production: ~150

Minneapolis

US



Mankato



- Urology care products
- Number of employees in production: ~150

- Skin care products
- Ostomy care accessories
- Number of employees in production: ~100

France

Sarlat



- Disposable surgical urology products
- Number of employees in production: ~200



.

Production sites

Hungary

Tatabánya



- Ostomy care products
- Adhesives
- Continence care products
- Urology care products
- Number of employees in production: ~1,700

China

Zhuhai



- Continence care products
- Ostomy care products
- Machine building
- Number of employees in production: ~ 900

Tata



- Postponement & packaging
- Cross docking
- Warehousing
- Distribution & shipping
- Number of employees: ~300

Nyírbátor



- Catheter care products
- Continence care products
- Wound care products (incl. Compeed)
- Number of employees in production: ~2,100



Contact Investor Relations

Holtedam 1 DK-3050 Humlebæk Denmark



Ellen Bjurgert Director, Investor Relations Tel. direct: +45 4911 3376 Office: +45 4911 1800 Fax: +45 4911 1555 dkebj@coloplast.com



Rasmus Sørensen

 Senior Manager, Investor Relations

 Tel. direct:
 +45 4911 1786

 Office:
 +45 4911 1800

 Fax:
 +45 4911 1555

 dkraso@coloplast.com



 Anne-Sofie Søegaard

 IR Coordinator

 Tel. direct:
 +45 4911 1924

 Office:
 +45 4911 1800

 Fax:
 +45 4911 1555

 dkasso@coloplast.com



 Sine Flinck

 Student Assistant

 Tel. direct:
 +45 4911 1934

 Office:
 +45 4911 1800

 Fax:
 +45 4911 1555

 dksfi@coloplast.com



Our mission

Making life easier for people with intimate healthcare needs

Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

Our vision

Setting the global standard for listening and responding

